Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 7/20 | 0.81 |
| ▸ | EGFR | P00533 | 6/20 | 0.81 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.71 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.71 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.71 |
| ▸ | WEE1 | P30291 | 8/20 | 0.69 |
| ▸ | SRC | P12931 | 5/20 | 0.69 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.69 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.69 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 3/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.62 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498213 | 1.00 | FGFR1 (0.81) | FGFR1EGFRRIPK2NOD2ACVR1 | |
| SCHEMBL5763306 | 0.90 | FGFR1 (1.00) | FGFR1EGFRRIPK2ACVR1WEE1 | |
| SCHEMBL13859034 | 0.86 | SRC (0.83) | FGFR1EGFRRIPK2NOD2ACVR1 | |
| SCHEMBL27956454 | 0.86 | RIPK2 (0.75) | FGFR1EGFRRIPK2NOD2ACVR1 | |
| SCHEMBL20564275 | 0.84 | RIPK2 (0.64) | FGFR1EGFRRIPK2NOD2ACVR1 | |
| SCHEMBL29498183 | 0.84 | RIPK2 (0.64) | FGFR1EGFRRIPK2NOD2ACVR1 | |
| SCHEMBL22681324 | 0.84 | FGFR1 (0.84) | FGFR1EGFRRIPK2NOD2ACVR1 | |
| SCHEMBL13859099 | 0.83 | RIPK2 (0.71) | FGFR1EGFRRIPK2NOD2ACVR1 | |
| SCHEMBL20564628 | 0.83 | RIPK2 (1.00) | FGFR1EGFRRIPK2NOD2ACVR1 | |
| SCHEMBL13859325 | 0.82 | RIPK2 (0.70) | FGFR1EGFRRIPK2NOD2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2026-05-12 | — | — | US | disclosed |
| US-20240327403-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3968991-B1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | UNIV HOUSTON SYSTEM (US) | 2024-07-31 | — | — | EP | disclosed |
| US-12012402-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-06-18 | — | — | US | disclosed |
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220064163-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-03-03 | — | — | US | disclosed |
| US-11174255-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174255-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-11-16 | — | — | US | disclosed |
| US-11136386-B2 | Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A) | PROMETHEUS BIOSCIENCES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210277477-A1 | METHODS OF TREATING REFRACTORY INFLAMMATORY DISEASE USING TRANSCRIPTOMIC AND GENETIC RISK SIGNATURES | CEDARS-SINAI MEDICAL CENTER | 2021-09-09 | — | — | US | disclosed |
| US-20210101988-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | CEDARS-SINAI MEDICAL CENTER | 2021-04-08 | — | — | US | disclosed |
| US-20210079473-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING SEVERE CROHN'S DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-18 | — | — | US | disclosed |
| WO-2020232190-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020232125-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200362025-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | CEDARS-SINAI MEDICAL CENTER | 2020-11-19 | — | — | US | disclosed |
| WO-2020139748-A1 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASES THAT TARGET RIPK2 | CEDARS-SINAI MEDICAL CENTER (US) | 2020-07-02 | — | — | WO | disclosed |
| US-20200172536-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200172536-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-06-04 | — | — | US | disclosed |
| WO-2018213219-A1 | PYRIDO[2,3-D]PYRIMIDIN-7ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200362025-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | FGFR1 2951/4885EGFR 2719/4885RIPK2 4403/4885 |
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | FGFR1 2951/4885EGFR 2719/4885RIPK2 4403/4885 |
| US-11174255-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | FGFR1 434/4885EGFR 1150/4885RIPK2 1/4885 |
| US-20200172536-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | RIPK2, RIPK1, RIPK4 | FGFR1 434/4885EGFR 1150/4885RIPK2 1/4885 |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | FGFR1 2951/4885EGFR 2719/4885RIPK2 4403/4885 |
| US-20240327403-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | RIPK2, RIPK1, RIPK4 | FGFR1 534/4885EGFR 1321/4885RIPK2 1/4885 |
| US-20210101988-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | FGFR1 2951/4885EGFR 2719/4885RIPK2 4403/4885 |
| US-20220064163-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | RIPK2, RIPK1, RIPK4 | FGFR1 534/4885EGFR 1321/4885RIPK2 1/4885 |
| US-11136386-B2 | Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A) | LTA, TLL1, TNF | FGFR1 3512/4885EGFR 3850/4885RIPK2 2417/4885 |
| US-12012402-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | FGFR1 534/4885EGFR 1321/4885RIPK2 1/4885 |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | FGFR1 996/4885EGFR 705/4885RIPK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.